Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

NCT02776215 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Circadian Rhythm Sleep Disorders
Non-24 Hour Sleep-Wake Disorder
Autism Spectrum Disorder
Smith-Magenis Syndrome

Interventions

DRUG: tasimelteon

Sponsor

Vanda Pharmaceuticals